Wednesday, February 05, 2025
MAIA is a targeted therapy, immuno-oncology company focused on the development and commercialization of potential first-in-class drugs with novel mechanisms of action that are intended to meaningfully improve and extend the lives of people with cancer. Our lead program is THIO, a potential first-in-class cancer telomere targeting agent in clinical development for the treatment of NSCLC patients with telomerase-positive cancer cells. For more information, please visit www.maiabiotech.com.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
MAIA Provides Phase 2 Interim Data Update In NSCLC. The Phase 2 THIO-101 trial is testing the combination of THIO with cemiplimab (Libtayo), a PD-1 checkpoint inhibitor from Regeneron, in patients with advanced non-small lung cancer (NSCLC). Median overall survival was 16.9 months, compared with expected survival of 5.8 months. Importantly, the lower limit of the statistical confidence intervals for the trial shows a 99% chance of surviving 10.8 months, a statistically significant result.
Combination Uses Two Mechanisms Of Action. The THIO-101 trial combines the killing effects from THIO with the PD-1 inhibition from cemiplimab. THIO uses its telomere targeting to damage cancer cell DNA, causing cell death. This also stimulates an immune response in the tumor through the cGAS/STING pathway and T-cell responses. Cemiplimab provides a second mechanism, allowing the immune cells to recognize and kill the cancer cells.
Get the Full Report
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
